Shine-On Biomedical Co., Ltd.

As of June 30, 2026, Shine-On Biomedical Co., Ltd. carries a market capitalization of 3.17B, placing it among publicly traded companies globally. Its enterprise value stands at 2.36B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Shine-On Biomedical Co., Ltd. has 49.80M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Shine-On Biomedical Co., Ltd. maintains a current ratio of 14.17, meaning it holds 14.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Shine-On Biomedical Co., Ltd.'s stock has declined approximately 11.14% over the past 52 weeks. The 50-day moving average sits at 64.12, while the 200-day moving average is 65.78.

As of June 30, 2026, Shine-On Biomedical Co., Ltd. holds 808.81M in cash and equivalents against 680,000.00 in total debt, resulting in a net debt position of -61.81M. Total book value stands at 791.21M, with working capital of 776.42M providing operational flexibility.